1887
Rapid communication Open Access
Like 0

Abstract

An individualised blood donor selection policy was implemented in the United Kingdom from summer 2021. We have investigated the impact of this policy by comparing the extent of undeclared use of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) before and after this change. The rate of PrEP usage in syphilis-positive male blood donors has not changed since individualised donor assessment was implemented but provides continuing evidence of undisclosed PrEP use which may be associated with current or past higher-risk sexual behaviours.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.11.2300135
2023-03-16
2024-07-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.11.2300135
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/11/eurosurv-28-11-1.html?itemId=/content/10.2807/1560-7917.ES.2023.28.11.2300135&mimeType=html&fmt=ahah

References

  1. Advisory Committee on the Safety of Blood. Tissues and Organs (SaBTO). Can donor selection policy move from a population-based donor selection policy to one based on a more individualised risk assessment? Conclusions from the For the Assessment of Individualised Risk (FAIR) group. SaBTO; 2020. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/21001/fair_sabto_20201211.pdf
  2. Sewell J, Fakoya I, Lampe FC, Howarth A, Phillips A, Burns F, et al. Effectiveness of interventions aimed at reducing HIV acquisition and transmission among gay and bisexual men who have sex with men (GBMSM) in high income settings: A systematic review. PLoS One. 2022;17(10):e0276209.  https://doi.org/10.1371/journal.pone.0276209  PMID: 36260550 
  3. Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee (JPAC). Change notification No. 04 – 2019. Pre- and post-exposure prophylaxis for HIV prevention– applies to the whole blood and components donor selection guidelines. Sheffield: JPAC; 2019. Available from https://www.transfusionguidelines.org/document-library/change-notifications/change-notifications-issued-in-2019
  4. Harvala H, Reynolds C, Ijaz S, Maddox V, Penchala SD, Amara A, et al. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. Sex Transm Infect. 2022;98(2):132-5.  https://doi.org/10.1136/sextrans-2021-054981  PMID: 33782147 
  5. Harvala H, Reynolds C, Fabiana A, Tossell J, Bulloch G, Brailsford S, et al. Lessons learnt from syphilis-infected blood donors: a timely reminder of missed opportunities. Sex Transm Infect. 2022;98(4):293-7. PMID: 34380778 
  6. Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, et al. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. J Acquir Immune Defic Syndr. 2013;62(3):275-81.  https://doi.org/10.1097/QAI.0b013e3182829bd0  PMID: 23274933 
  7. Nash S, Dietrich J, Ssemata AS, Herrera C, O’Hagan K, Else L, et al. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial. Trials. 2020;21(1):900.  https://doi.org/10.1186/s13063-020-04760-x  PMID: 33121503 
  8. O’Halloran C, Owen G, Croxford S, Sims LB, Gill ON, Nutland W, et al. Current experiences of accessing and using HIV pre-exposure prophylaxis (PrEP) in the United Kingdom: a cross-sectional online survey, May to July 2019. Euro Surveill. 2019;24(48):1900693.  https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900693  PMID: 31796157 
  9. Custer B, Quiner C, Haaland R, Martin A, Stone M, Reik R, et al. HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. Blood. 2020;136(11):1351-8.  https://doi.org/10.1182/blood.2020006890  PMID: 32645148 
  10. Gosbell IB, Hoad VC, Styles CE, Lee J, Seed CR. Undetectable does not equal untransmittable for HIV and blood transfusion. Vox Sang. 2019;114(6):628-30.  https://doi.org/10.1111/vox.12790  PMID: 31106848 
  11. To KW, Lee SS. A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections. HIV Med. 2021;22(2):75-82.  https://doi.org/10.1111/hiv.12989  PMID: 33140556 
  12. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, et al. Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis. J Acquir Immune Defic Syndr. 2017;76(4):e104-6.  https://doi.org/10.1097/QAI.0000000000001534  PMID: 29076941 
  13. de Souza MS, Pinyakorn S, Akapirat S, Pattanachaiwit S, Fletcher JLK, Chomchey N, et al. Initiation of antiretroviral therapy during acute HIV‐1 infection leads to a high rate of nonreactive HIV serology. Clin Infect Dis. 2016;63(4):555-61.  https://doi.org/10.1093/cid/ciw365  PMID: 27317797 
  14. Elliott T, Sanders EJ, Doherty M, Ndung’u T, Cohen M, Patel P, et al. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. J Int AIDS Soc. 2019;22(12):e25419.  https://doi.org/10.1002/jia2.25419  PMID: 31850686 
  15. Foster K, Sullivan AK, Hughes G, Simms I, Fifer H, Mohammed H, et al. Addressing the increase in syphilis in England: PHE action plan. London: Public Health England; 2019. Available from: https://www.gov.uk/government/publications/syphilis-public-health-england-action-plan
/content/10.2807/1560-7917.ES.2023.28.11.2300135
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error